OABI
Price
$1.62
Change
-$0.02 (-1.22%)
Updated
Aug 29, 03:59 PM (EDT)
Capitalization
236.09M
RXRX
Price
$4.70
Change
-$0.16 (-3.29%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
2.11B
68 days until earnings call
Interact to see
Advertisement

OABI vs RXRX

Header iconOABI vs RXRX Comparison
Open Charts OABI vs RXRXBanner chart's image
OmniAb
Price$1.62
Change-$0.02 (-1.22%)
Volume$490
Capitalization236.09M
Recursion Pharmaceuticals
Price$4.70
Change-$0.16 (-3.29%)
Volume$89.3K
Capitalization2.11B
OABI vs RXRX Comparison Chart in %
Loading...
OABI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OABI vs. RXRX commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OABI is a Buy and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (OABI: $1.64 vs. RXRX: $4.86)
Brand notoriety: OABI and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OABI: 65% vs. RXRX: 50%
Market capitalization -- OABI: $236.09M vs. RXRX: $2.11B
OABI [@Biotechnology] is valued at $236.09M. RXRX’s [@Biotechnology] market capitalization is $2.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OABI’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • OABI’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both OABI and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OABI’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • OABI’s TA Score: 4 bullish, 6 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both OABI and RXRX are a bad buy in the short-term.

Price Growth

OABI (@Biotechnology) experienced а -8.89% price change this week, while RXRX (@Biotechnology) price change was +1.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.74%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +29.97%.

Reported Earning Dates

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-0.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.11B) has a higher market cap than OABI($236M). RXRX YTD gains are higher at: -28.033 vs. OABI (-53.672). OABI has higher annual earnings (EBITDA): -51.78M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. OABI (41.6M). OABI has less debt than RXRX: OABI (21.8M) vs RXRX (88.1M). RXRX has higher revenues than OABI: RXRX (64.5M) vs OABI (23M).
OABIRXRXOABI / RXRX
Capitalization236M2.11B11%
EBITDA-51.78M-583.64M9%
Gain YTD-53.672-28.033191%
P/E RatioN/AN/A-
Revenue23M64.5M36%
Total Cash41.6M525M8%
Total Debt21.8M88.1M25%
TECHNICAL ANALYSIS
Technical Analysis
OABIRXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
56%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 25 days ago
68%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
OABI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SGGTF0.04N/A
N/A
SIGNATURE RES LTD CDA
KKPCF28.09N/A
N/A
Kaken Pharmaceutical Co., Ltd.
FOSUY17.50N/A
N/A
Fosun International, Ltd.
PGPHF1404.84-3.33
-0.24%
Partners Group Holding Zug Namen-Akt
PBIGF0.17-0.04
-18.39%
Paradigm Biopharmaceuticals Ltd.

OABI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OABI has been loosely correlated with BEAM. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OABI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OABI
1D Price
Change %
OABI100%
+1.86%
BEAM - OABI
41%
Loosely correlated
-0.06%
ALEC - OABI
38%
Loosely correlated
-0.42%
RXRX - OABI
38%
Loosely correlated
-0.51%
TECH - OABI
37%
Loosely correlated
-3.36%
IMNM - OABI
37%
Loosely correlated
-0.50%
More